Data and analytics company, GlobalData, has stated that according to its latest research immune-based gene therapy candidates should prevail in oncology, however, this novel approach is unchartered territory in oncology and will require new regulatory guidelines.
DNA Sequencing
Its recent report, ‘Gene Therapy in Oncology’, provides an overview of the current competitive landscape of gene therapies in oncology and the regulatory framework concerning clinical development and commercialisation across the US, France, Germany, Italy, Spain, UK, Japan, and China (8MM). Additionally, it details the Phase III and Phase II cancer gene therapy candidates that are expected to enter the oncology space within the next ten years and provides key opinion leader insights on the impact of cancer gene therapies in various treatment paradigms in the oncology space as well as a payer perspective on the cost and reimbursement of novel cancer gene therapies.